ArticleBritish journal of pharmacology2006
Rapamycin induces regression of endometriotic lesions by inhibiting neovascularization and cell proliferation.
Article in British journal of pharmacology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- Pentoxifylline for the treatment of endometriosis-associated pain and infertility.The Cochrane database of systematic reviews · 2021Pooled it
- Rapamycin improves endometriosis‑related infertility involving ovarian senescence via the PPARα/IGFBP2 pathway.Molecular medicine reports · 2026Article
- Targeting angiogenesis in endometriosis: a systematic review and network meta-analysis of VEGF-directed pharmacotherapies.Frontiers in reproductive health · 2025Article
- Non-Hormonal Therapy for Endometriosis Based on Angiogenesis, Oxidative Stress and Inflammation.International journal of fertility & sterility · 2024Review
- A Comprehensive Review of the Efficacy and Safety of Dopamine Agonists for Women with Endometriosis-associated Infertility from Inception to July 31, 2022.Acta medica Philippina · 2024Article
- Antilipidemic ezetimibe induces regression of endometriotic explants in a rat model of endometriosis with its anti-inflammatory and anti-angiogenic effects.Naunyn-Schmiedeberg's archives of pharmacology · 2022Article
- Impacts of endometrioma on ovarian aging from basic science to clinical management.Frontiers in endocrinology · 2022Review
- New therapeutic approaches for endometriosis besides hormonal therapy.Chinese medical journal · 2019Review
- Everolimus as an mTOR Inhibitor Suppresses Endometriotic Implants: an Experimental Rat Study.Geburtshilfe und Frauenheilkunde · 2017Article
- Effect of rapamycin on endometriosis in mice.Experimental and therapeutic medicine · 2016Article
- Inhibition of Hyaluronic Acid Synthesis Suppresses Angiogenesis in Developing Endometriotic Lesions.PloS one · 2016Article
- Angiogenesis and endometriosis.Obstetrics and gynecology international · 2013Article
- In vitro and in vivo evaluation of the anti-angiogenic actions of 4-hydroxybenzyl alcohol.British journal of pharmacology · 2011Article
- Intravital microscopy in the mouse dorsal chamber model for the study of solid tumors.American journal of cancer research · 2011Article
- High-resolution ultrasound imaging: a novel technique for the noninvasive in vivo analysis of endometriotic lesion and cyst formation in small animal models.The American journal of pathology · 2010Article
- Intravital microscopy of tumor angiogenesis and regression in the dorsal skin fold chamber: mechanistic insights and preclinical testing of therapeutic strategies.Clinical & experimental metastasis · 2009Review
- Expansion of microvascular networks in vivo by phthalimide neovascular factor 1 (PNF1).Biomaterials · 2008Article
- Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice.Proceedings of the National Academy of Sciences of the United States of America · 2008Article
- Rapamycin affects early fracture healing in mice.British journal of pharmacology · 2008Article
- PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel.Clinical cancer research : an official journal of the American Association for Cancer Research · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeRapamycin is a widely used drug with antifungal, immunosuppressant and antiangiogenic effects. Herein, we studied whether immunosuppressive doses of rapamycin are capable of influencing endometriotic lesions. EXPERIMENTAL APPROACH: We tested in vitro the potential of rapamycin to inhibit endothelial cell sprouting using the aortic ring assay and we further studied its effect on the expression of proliferating cell nuclear antigen (PCNA), apoptotic cell death-associated activated caspase-3 and vascular endothelial growth factor (VEGF) in cultured endometrial tissue fragments. In addition, we analyzed the drug in vivo after induction of endometriotic lesions by transplanting isolated endometrial fragments into the dorsal skinfold chamber of Syrian golden hamsters. Using intravital fluorescence microscopy, we repetitively analyzed angiogenesis, neovascularization and microcirculatory parameters over a time period of 14 days in rapamycin-treated animals and DMSO-treated controls. KEY
resultsAdministration of rapamycin significantly reduced the size of the endometriotic lesions. This was associated by inhibition of VEGF-mediated angiogenesis as indicated by a suppression of endothelial cell sprouting in vitro and a reduction of microvessel density in endometriotic lesions in vivo. Moreover, rapamycin directly inhibited cell proliferation within endometrial tissue, while manifestation of apoptotic cell death remained unaffected. CONCLUSIONS AND IMPLICATIONS: Our data indicate that administration of rapamycin may represent a novel therapeutic approach for an antiangiogenic treatment of endometriosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.